drugset / Trial / NCT00502060
Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer
Timeline
- Start
- 2004-08
- Primary completion
- 2006-06
- Completion
- 2006-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | — | Oral |
| Background | Gefitinib | Small molecule | 250 mg | Oral |
| Background | Gefitinib | Small molecule | 500 mg | Oral |
Indications
No indication recorded.